# Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

> **NCT04463771** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 206 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** retifanlimab
- **DRUG:** epacadostat
- **DRUG:** pemigatinib
- **DRUG:** INCAGN02385
- **DRUG:** INCAGN02390

## Key facts

- **NCT ID:** NCT04463771
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-26
- **Primary completion:** 2026-04-14
- **Final completion:** 2026-07-10
- **Target enrollment:** 206 (ACTUAL)
- **Last updated:** 2025-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04463771

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04463771, "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04463771. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*